Discovery of DS-1558: A potent and orally bioavailable GPR40 agonist

ACS Medicinal Chemistry Letters

Volumn 6, Issue 3, 2015, Pages 266-270

  Takano, Rieko ^a   Yoshida, Masao ^a   Inoue, Masahiro ^a   Honda, Takeshi ^a   Nakashima, Ryutaro ^a   Matsumoto, Koji ^a   Yano, Tatsuya ^a   Ogata, Tsuneaki ^a   Watanabe, Nobuaki ^a   Hirouchi, Masakazu ^a   Yoneyama, Tomoko ^a   Ito, Shuichiro ^a   Toda, Narihiro ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

agonist; diabetes; glucose lowering; GPR40; insulin secretagogue

Indexed keywords

(3) 3 ETHOXY 3 [4 [[(1) 4 (TRIFLUOROMETHYL) 2,3 DIHYDRO 1 H INDEN 1 YL]OXY]PHENYL]PROPANOIC ACID; DS 1558; G PROTEIN COUPLED RECEPTOR 40 AGONIST; ORAL ANTIDIABETIC AGENT; RECEPTOR; SITAGLIPTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; HUMAN; HUMAN CELL; HYPOGLYCEMIA; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RAT; RISK; ZUCKER DIABETIC FATTY RAT;

RATTUS;

EID: 84924677753     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500391n     Document Type: Article

References (32)

1. Danaei, G.; Finucane, M. M.; Lu, Y.; Singh, G. M.; Cowan, M. J.; Paciorek, C. J.; Lin, J. K.; Farzadfar, F.; Khang, Y. H.; Stevens, G. A.; Rao, M.; Ali, M. K.; Riley, L. M.; Robinson, C. A.; Ezzati, M. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants Lancet 2011, 378, 31-40
2. WHO. Diabetes Fact Sheet, No. 312, October 2013.
3. Doyle, M. E.; Egan, J. M. Pharmacological agents that directly modulate insulin secretion Pharmacol. Rev. 2003, 55, 105-131
4. Seino, Y.; Rasmussen, M. F.; Nishida, T.; Kaku, K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes Curr. Med. Res. Opin. 2010, 26, 1013-1022
5. Maedler, K.; Carr, R. D.; Bosco, D.; Zuellig, R. A.; Berney, T.; Donath, M. Y. Sulfonylurea induced β-cell apoptosis in cultured human islets J. Clin. Endocrinol. Metab. 2005, 90, 501-506
6. Del Guerra, S.; Marselli, L.; Lupi, R.; Boggi, U.; Mosca, F.; Benzi, L.; Del Prato, S.; Marchetti, P. Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets J. Diabetes Complications 2005, 19, 60-64
7. Avery, M. A.; Mizuno, C. S.; Chittiboyina, A. G.; Kurtz, T. W.; Pershadsingh, H. A. Type 2 diabetes and oral antihyperglycemic drugs Curr. Med. Chem. 2008, 15, 61-74
8. Barnett, A. H. Thiazolidinediones and cardiovascular outcomes Br. J. Diabetes Vasc. Dis. 2008, 8, 45-49
9. Rendell, M. The role of sulphonylureas in the management of type 2 diabetes mellitus Drugs 2004, 64, 1339-1358
10. Ohishi, T.; Yoshida, S. The therapeutic potential of GPR119 agonists for type 2 diabetes Expert Opin. Invest. Drugs 2012, 21, 321-328
11. Toda, N.; Hao, X.; Ogawa, Y.; Oda, K.; Yu, M.; Fu, Z.; Chen, Y.; Kim, Y.; Lizarzaburu, M.; Lively, S.; Lawlis, S.; Murakoshi, M.; Nara, F.; Watanabe, N.; Reagan, J. D.; Tian, H.; Fu, A.; Motani, A.; Liu, Q.; Lin, Y.-J.; Zhuang, R.; Xiong, Y.; Fan, P.; Medina, J.; Li, L.; Izumi, M.; Okuyama, R.; Shibuya, S. Potent and orally bioavailable GPR142 agonists as novel insulin secretagogues for the treatment of type 2 diabetes ACS Med. Chem. Lett. 2013, 4, 790-794
12. Itoh, Y.; Kawamata, Y.; Harada, M.; Kobayashi, M.; Fujii, R.; Fukusumi, S.; Ogi, K.; Hosoya, M.; Tanaka, Y.; Uejima, H.; Tanaka, H.; Maruyama, M.; Satoh, R.; Okubo, S.; Kizawa, H.; Komatsu, H.; Matsumura, F.; Noguchi, Y.; Shinohara, T.; Hinuma, S.; Fujisawa, Y.; Fujino, M. Free fatty acids regulate insulin secretion from pancreatic β-cells through GPR40 Nature 2003, 422, 173-176
13. Briscoe, C. P.; Tadayyon, M.; Andrews, J. L.; Benson, W. G.; Chambers, J. K.; Eilert, M. M.; Ellis, C.; Elshourbagy, N. A.; Goetz, A. S.; Minnick, D. T.; Murdock, P. R.; Sauls, H. R., Jr.; Shabon, U.; Spinage, L. D.; Strum, J. C.; Szekeres, P. G.; Tan, K. B.; Way, J. M.; Ignar, D. M.; Wilson, S.; Muir, A. I. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids J. Biol. Chem. 2003, 278, 11303-11311
14. Kotarsky, K.; Nilsson, N. E.; Flodgren, E.; Owman, C.; Olde, B. A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs Biochem. Biophys. Res. Commun. 2003, 301, 406-410
15. Shapiro, H.; Shachar, S.; Sekler, I.; Hershfinkel, M.; Walker, M. D. Role of GPR40 in fatty acid action on the β cell line INS-1E Biochem. Biophys. Res. Commun. 2005, 335, 97-104
16. 2+ channel and link to insulin release J. Physiol. Endoclinol. Metab. 2005, 289, E670-E677
17. Tan, C. P.; Feng, Y.; Zhou, Y. P.; Eiermann, G. J.; Petrov, A.; Zhou, C.; Lin, S.; Salituro, G.; Meinke, P.; Mosley, R.; Akiyama, T. E.; Einstein, M.; Kumar, S.; Berger, J. P.; Mills, S. G.; Thornberry, N. A.; Yang, L.; Howard, A. D. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice Diabetes 2008, 57, 2211-2219
18. Burant, C. F.; Viswanathan, P.; Marcinak, J.; Cao, C.; Vakilynejad, M.; Xie, B.; Leifke, E. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial Lancet 2012, 379, 1403-1411
19. Tsujihata, Y.; Itoh, R.; Suzuki, M.; Harada, A.; Negoro, N.; Yasuma, T.; Momose, Y.; Takeuchi, K. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats J. Pharmacol. Exp. Ther. 2011, 339, 228-237
20. Bharate, S. B.; Nemmani, K. VS.; Vishwakarma, R. A. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes Expert Opin. Ther. Pat. 2009, 19, 237-264
21. Holliday, N. D.; Watson, S. J.; Brown, A. J. H. Drug discovery opportunities and challenges at G protein coupled receptors for long chain free fatty acids Front. Endocrinol. 2011, 2, 112
22. Negoro, N.; Sasaki, S.; Mikami, S.; Ito, M.; Suzuki, M.; Tsujihata, Y.; Ito, R.; Harada, A.; Takeuchi, K.; Suzuki, N.; Miyazaki, J.; Santou, T.; Odani, T.; Kanzaki, N.; Funami, M.; Tanaka, T.; Kogame, A.; Matsunaga, S.; Yasuma, T.; Momose, Y. Discovery of TAK-875: A potent, selective, and orally bioavailable GPR40 agonist ACS Med. Chem. Lett. 2010, 1, 290-294
23. Christiansen, E.; Due-Hansen, M. E.; Urban, C.; Merten, N.; Pfleiderer, M.; Karlsen, K. K.; Rasmussen, S. S.; Steensgaard, M.; Hamacher, A.; Schmidt, J.; Drewke, C.; Petersen, R. K.; Kristiansen, K.; Ullrich, S.; Kostenis, E.; Kassack, M. U.; Ulven, T. Structure-activity study of dihydrocinnamic acids and discovery of the potent FFA1 (GPR40) agonist TUG-469 ACS Med. Chem. Lett. 2010, 1, 345-349
24. Houze, J. B.; Zhu, L.; Sun, Y.; Akerman, M.; Qiu, W.; Zhang, A. J.; Sharma, R.; Schmitt, M.; Wang, Y.; Liu, J.; Liu, J.; Medina, J. C.; Reagan, J. D.; Luo, J.; Tonn, G.; Zhang, J.; Lu, J. Y. L.; Chen, M.; Lopez, E.; Nguyen, K.; Yang, L.; Tang, L.; Tian, H.; Shuttleworth, S. J.; Lin, D. C. -H. AMG 837: A potent, orally bioavailable GPR40 agonist Bioorg. Med. Chem. Lett. 2012, 22, 1267-1270
25. Zhou, C.; Tang, C.; Chang, E.; Ge, M.; Lin, S.; Cline, E.; Tan, C. P.; Feng, Y.; Zhou, Y. P.; Eiermann, G. J.; Petrov, A.; Salituro, G.; Meinke, P.; Mosley, R.; Akiyama, T. E.; Einstein, M.; Kumar, S.; Berger, J.; Howard, A. D.; Thornberry, N.; Mills, S. G.; Yang, L. Discovery of 5-aryloxy-2,4-thiazolidinediones as potent GPR40 agonists Bioorg. Med. Chem. Lett. 2010, 20, 1298-1301
26. McKeown, S. C.; Corbett, D. F.; Goetz, A. S.; Littleton, T. R.; Bigham, E.; Briscoe, C. P.; Peat, A. J.; Watson, S. P.; Hickey, D. M. B. Solid phase synthesis and SAR of small molecule agonists for the GPR40 receptor Bioorg. Med. Chem. Lett. 2007, 17, 1584-1589
27. Christiansen, E.; Hansen, S. V. F.; Urban, C.; Hudson, B. D.; Wargent, E. T.; Grundmann, M.; Jenkins, L.; Zaibi, M.; Stocker, C. J.; Ullrich, S.; Kostenis, E.; Kassack, M. U.; Milligan, G.; Cawthorne, M. A.; Ulven, T. Discovery of TUG-770: A highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist for treatment of type 2 diabetes ACS Med. Chem. Lett. 2013, 4, 441-445
28. Brown, S. P.; Dransfield, P. J.; Vimolratana, M.; Jiao, X.; Zhu, L.; Pattaropong, V.; Sun, Y.; Liu, J.; Luo, J.; Zhang, J.; Wong, S.; Zhung, R.; Guo, Q.; Li, F.; Medina, J. C.; Swaminath, G.; Lin, D. C. -H.; Houze, J. B. Discovery of AM-1638: a potent and orally bioavailable GPR40/FFA1 full agonist ACS Med. Chem. Lett. 2012, 3, 726-730
29. Takano, R.; Yoshida, M.; Inoue, M.; Honda, T.; Nakashima, R.; Matsumoto, K.; Yano, T.; Ogata, T.; Watanabe, N.; Toda, N. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR4o agonists Bioorg. Med. Chem. Lett. 2014, 24, 2949-2953
30. Fujii, A.; Hashiguchi, S.; Uematsu, N.; Ikariya, T.; Noyori, R. Ruthenium(II)-catalyzed asymmetric transfer hydrogenation of ketones using a formic acid-triethylamine mixture J. Am. Chem. Soc. 1996, 118, 2521-2522
31. Brooks, D. W.; Lu, L. D.-L.; Masamune, S. C -Acylation under virtually neutral conditions Angew. Chem., Int. Ed. 1979, 18, 72-74
32. Nakashima, R.; Yano, T.; Ogawa, J.; Tanaka, N.; Toda, N.; Yoshida, M.; Takano, R.; Inoue, M.; Honda, T.; Kume, S.; Matsumoto, K. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists Eur. J. Pharmacol. 2014, 737, 194-201